Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
|Articles|November 8, 2022
- Pharmaceutical Executive-11-01-2022
- Volume 42
- Issue 11
Pharmaceutical Executive, November 2022 Issue (PDF)
Advertisement
Articles in this issue
almost 4 years ago
Labs and Computing Power: The Missing Link for a Revolution by 2030almost 4 years ago
A Culture of Quality: The Catalyst to Accelerate Innovationalmost 4 years ago
A Mission of the Heartalmost 4 years ago
The New Reality for Industry Dealmaking May be Setting Inalmost 4 years ago
Is ESG a ‘Protection Racket’ or Long-Term Value Contributor?almost 4 years ago
Digital Biomarkers Could Reshape CNS Diagnosis, Treatmentalmost 4 years ago
Long-Sought Reforms To EU Drug Rules Hit A Snag—What Now?almost 4 years ago
Recaps, Live & In Personabout 4 years ago
FDA Keeps Its User Fees, but Fails to Gain Important ReformsAdvertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
2
FDA Approves Ilumya for Adults With Active Psoriatic Arthritis
3
Closing the Pediatric Evidence Gap
4
Post-Exposure Prophylaxis Is the Missing Piece: Q&A with Florin Draica
5